Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 12/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 8/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6061368 | 0.90 | MEN1 (0.43) | CNR2MEN1KMT2ASMN1; SMN2CNR1 | |
| SCHEMBL15163634 | 0.90 | MEN1 (0.41) | CNR2MEN1KMT2ASMN1; SMN2CNR1 | |
| SCHEMBL5540519 | 0.89 | GRIN2B (0.41) | CNR2CNR1PIK3CAL3MBTL1 | |
| SCHEMBL15163633 | 0.89 | CNR2 (0.46) | CNR2MEN1KMT2ASMN1; SMN2CNR1 | |
| SCHEMBL5538863 | 0.88 | L3MBTL1 (0.42) | HTTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL5546735 | 0.88 | L3MBTL1 (0.40) | HTTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL6062008 | 0.88 | CNR2 (0.40) | CNR2MEN1KMT2ASMN1; SMN2CNR1 | |
| SCHEMBL5538810 | 0.86 | CNR2 (0.49) | CNR2MEN1KMT2ASMN1; SMN2CNR1 | |
| SCHEMBL5546739 | 0.86 | L3MBTL1 (0.38) | HTTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL5546952 | 0.86 | L3MBTL1 (0.41) | HTTCNR2MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | HTT 3334/4885CNR2 3954/4885MEN1 4802/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | HTT 3463/4885CNR2 4810/4885MEN1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.